Physician profile
Cassandra E Olson
NPI 1174156046
$924.95
in general payments reported to CMS, 2019-2025
16 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.16 · 2022: $202 · 2023: $88.53 · 2024: $253 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $212.53 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $137.53 | 2025 | Penmenvy, Bexsero |
| Corium, LLC | $109.33 | 2022-2023 | Azstarys |
| Sanofi Pasteur INC. | $92.99 | 2024-2025 | |
| Sobi, INC | $85.85 | 2022 | |
| Ironshore Pharmaceuticals INC. | $78.50 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $34.67 | 2025 | Jornay Pm |
| Abbvie INC. | $30.86 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.35 | 2023 | |
| Genzyme Corporation | $23.67 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $18.23 | 2024 | Flumist Quadrivalent |
| Pfizer INC. | $16.50 | 2024 | |
| Tris Pharma INC | $16.47 | 2021 | |
| Noven Therapeutics, LLC | $16.10 | 2025 | Xelstrym |
| Kyowa Kirin, INC. | $14.21 | 2024 | Crysvita |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $13.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.